Literature DB >> 27505863

Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients.

Veronika Brynychova1, Marie Ehrlichova2, Viktor Hlavac1, Vlasta Nemcova-Furstova3, Vaclav Pecha4, Jelena Leva4, Marketa Trnkova5, Marcela Mrhalova6, Roman Kodet6, David Vrana7, Jan Kovar3, Radka Vaclavikova8, Ivan Gut8, Pavel Soucek9.   

Abstract

Microtubules are vitally important for eukaryotic cell division. Therefore, we evaluated the relevance of mitotic kinesin KIF14, protein-regulating cytokinesis 1 (PRC1), and citron kinase (CIT) for the prognosis of breast carcinoma patients. Transcript levels were assessed by quantitative real-time PCR in tissues from two independent groups of breast carcinoma patients and compared with clinical data. Tissue PRC1 protein levels were estimated using immunoblotting, and the PRC1 tagged haplotype was analyzed in genomic DNA. A functional study was performed in MDA-MB-231 cells in vitro. KIF14, PRC1, and CIT transcripts were overexpressed in tumors compared with control tissues. Tumors without expression of hormonal receptors or high-grade tumors expressed significantly higher KIF14 and PRC1 levels than hormonally-positive or low-grade tumors. Patients with high intra-tumoral PRC1 levels had significantly worse disease-free survival than patients with low levels. PRC1 rs10520699 and rs11852999 polymorphisms were associated with PRC1 transcript levels, but not with patientś survival. Paclitaxel-induced PRC1 expression, but PRC1 knockdown did not modify the paclitaxel cytotoxicity in vitro. PRC1 overexpression predicts poor disease-free survival of patients with breast carcinomas. Genetic variability of PRC1 and the protein interaction with paclitaxel cytotoxicity do not explain this association.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breast carcinoma; Cytokinesis; Expression; Genetic; Marker

Mesh:

Substances:

Year:  2016        PMID: 27505863     DOI: 10.1016/j.biopha.2016.07.047

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.

Authors:  Theresa M Thole; Marco Lodrini; Johannes Fabian; Jasmin Wuenschel; Sebastian Pfeil; Thomas Hielscher; Annette Kopp-Schneider; Ulrike Heinicke; Simone Fulda; Olaf Witt; Angelika Eggert; Matthias Fischer; Hedwig E Deubzer
Journal:  Cell Death Dis       Date:  2017-03-02       Impact factor: 8.469

2.  Overexpression of microRNA-203 Suppresses Proliferation, Invasion, and Migration while Accelerating Apoptosis of CSCC Cell Line SCL-1.

Authors:  Wenyun Ting; Cheng Feng; Mingzi Zhang; Fei Long; Ming Bai
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-01       Impact factor: 8.886

3.  Comprehensive investigation of key biomarkers and pathways in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xiwen Liao; Tingdong Yu; Chengkun Yang; Ketuan Huang; Xiangkun Wang; Chuangye Han; Rui Huang; Xiaoguang Liu; Long Yu; Guangzhi Zhu; Hao Su; Wei Qin; Jianlong Deng; Xianmin Zeng; Bowen Han; Quanfa Han; Zhengqian Liu; Xin Zhou; Junqi Liu; Yizhen Gong; Zhengtao Liu; Jianlv Huang; Lei Lu; Xinping Ye; Tao Peng
Journal:  J Cancer       Date:  2019-09-07       Impact factor: 4.207

4.  Gene expression of cytokinesis regulators PRC1, KIF14 and CIT has no prognostic role in colorectal and pancreatic cancer.

Authors:  Vojtech Hanicinec; Veronika Brynychova; Jachym Rosendorf; Richard Palek; Vaclav Liska; Martin Oliverius; Zdenek Kala; Beatrice Mohelnikova-Duchonova; Ivona Krus; Pavel Soucek
Journal:  Oncol Lett       Date:  2021-06-09       Impact factor: 2.967

5.  Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.

Authors:  Gang Chen; Mingwei Yu; Jianqiao Cao; Huishan Zhao; Yuanping Dai; Yizi Cong; Guangdong Qiao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.